Cognoptix makes new appointments 

1750

Cognoptix has announced new appointments to their senior management team. Carl Sadowsky (Nova SE University, West Palm Beach, USA) has been appointed as chief medical officer, and Mike Kaswan (New York, USA) as chief financial officer. Cognoptix is a company dedicated to the early detection of Alzheimer’s disease (AD).

According to their press release, Sadowsky is nationally renowned physician and researcher in AD and neurodegenerative diseases. Sadowsky has conducted over 300 Alzheimer’s clinical trials, including the amyloid PET Amyvid trial and the IDEAS trial. He served on the scientific review board for Alzheimer’s Drug Discovery Foundations (ADDF) and serves on the Alzheon scientific advisory board. He is a fellow of the American Academy of Neurology.

Their press release states that Sadowsky also serves on Cognoptix’s Scientific Advisory Board which operates to advance clinical testing of Cognoptix’s Sapphire II device-drug combination eye scanner for early detection of AD.

Cognoptix further states that Mike Kaswan brings over 25 years of experience as a senior finance, chief executive, and venture capital officer of rapidly growing healthcare companies. A passionate entrepreneur, he will support the ongoing market strategies at Cognoptix. Kaswan co-founded and wrote original business plans for two companies that achieved combined cash exits of US$1.4 billion. He also co-founded a healthcare-focused venture capital firm that raised over $290 million in investment capital and built a private-equity backed start-up by acquisition with over 200 employees.

Susanne Wilke (Cognoptix, Old Greenwich, USA), stated, “I am delighted to have Carl and Mike join the Cognoptix team and support the company’s mission to launch the Sapphire II system, our transformational drug-device combination system for early detection of Alzheimer’s disease (AD).” She continued, “Both will be tremendous assets to Cognoptix, rounding out the formidable strength of the Cognoptix team.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here